Bulletin
Investor Alert

New York Markets Close in:

Revolution Medicines Inc.

NAS: RVMD

GO
/marketstate/country/us

Market open

 --Real time quotes

Oct 4, 2022, 1:09 p.m.

/zigman2/quotes/216320743/composite

$

19.56

Change

+0.03 +0.15%

Volume

Volume 140,944

Real time quotes

/zigman2/quotes/216320743/composite

Previous close

$ 19.53

$ 19.56

Change

+0.03 +0.15%

Day low

Day high

$19.53

$20.49

Open

52 week low

52 week high

$14.08

$34.16

Open

Flavia Borellini

Flavia Borellini is on the board of Cantargia AB, Revolution Medicines, Inc., Kartos Therapeutics, Inc. and Viracta Therapeutics, Inc. and Member of Roche Group.

Dr. Borellini previously occupied the position of Global Head-Hematology Franchise at AstraZeneca Plc and Chief Executive Officer of Acerta Pharma BV (a subsidiary of AstraZeneca Plc).

Dr. Borellini received a doctorate from Università degli Studi di Modena e Reggio Emilia.

Transactions

Date Shares Transaction Value
06/16/2022 5,200   Award at $0 per share. 0
06/22/2021 7,234   Award at $0 per share. 0

Officers and Executives

Dr. Mark A. Goldsmith
Chairman, President & Chief Executive Officer
Dr. Margaret A. Horn
Chief Operating Officer & General Counsel
Mr. Jack Anders
Chief Financial Officer
Dr. Stephen M. Kelsey
President-Research & Development
Dr. Walter Reiher
Chief Information Officer
Dr. Xiao Lin Wang
Executive Vice President-Clinical Development
Dr. Sushil Patel
Director
Ms. Luan M. Wilfong
Senior Vice President-Human Resources
Mr. Jeff Cislini
Secretary, Senior Vice President & General Counsel
Dr. Eric Schmidt
Independent Director
Dr. Flavia Borellini
Independent Director
Dr. Lorence H. Kim
Independent Director
Ms. Elizabeth McKee Anderson
Independent Director
Mr. Alexis A. Borisy
Lead Independent Director
Dr. Thilo Schroeder
Independent Director
Dr. Barbara L. Weber
Independent Director
Link to MarketWatch's Slice.